Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...
US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...
Eli Lilly (NYSE:LLY) on Thursday reported its Q4 ... LLY’s GLP-1 therapy tirzepatide, branded as Mounjaro and Zepbound for diabetes and weight loss, respectively, powered the company’s Q4 ...